Physician profile
Jenna Elsner
NPI 1750920583
$3,586.47
in general payments reported to CMS, 2019-2025
27 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,859 · 2022: $1,230 · 2024: $125 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.85 | 2021-2025 | |
| Lilly USA, LLC | $348.25 | 2021-2022 | |
| Novo Nordisk INC | $323.07 | 2021-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $247.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $240.77 | 2021-2025 | Farxiga, Breztri |
| Esperion Therapeutics, INC. | $209.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.76 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $142.15 | 2021 | |
| Amgen INC. | $126.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $122.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $109.05 | 2021-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $102.37 | 2021-2024 | Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.41 | 2021-2022 | |
| Daiichi Sankyo INC. | $82.99 | 2021-2022 | |
| Corium, LLC | $65.30 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $46.86 | 2021-2022 | |
| Pfizer INC. | $43.80 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.06 | 2021 | |
| Exact Sciences Corporation | $37.19 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $26.42 | 2021-2022 | |
| Almatica Pharma LLC | $19.78 | 2022 | |
| Genentech USA, INC. | $19.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.67 | 2022 | |
| Dexcom, INC. | $15.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Elsner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.